Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

max health limited - glycopyrronium bromide 0.5 mg/ml; neostigmine metilsulfate 2.5 mg/ml - solution for injection - active: glycopyrronium bromide 0.5 mg/ml neostigmine metilsulfate 2.5 mg/ml excipient: citric acid citric acid monohydrate dibasic sodium phosphate dodecahydrate sodium hydroxide water for injection - reversal of residual non-depolarising (competitive) neuromuscular block.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - glycopyrronium bromide, quantity: 0.2 mg/ml - injection, solution - excipient ingredients: water for injections; sodium hydroxide; hydrochloric acid; sodium chloride - 1.as a preoperative antimuscarinic to reduce salivary, tracheobronchial and pharyngeal secretions, and to reduce the acidity and volume of the gastric contents. 2.as a preoperative or intraoperative antimuscarinic to attenuate or prevent intraoperative bradycardia associated with the use of suxa-methonium or due to cardiac vagal reflexes. 3.to protect against the peripheral muscarinic actions (eg. bradycardia and excessive secretions) of anticholinesterases such as neostigmine or pyridostigmine given to reverse neuromuscular blockade produced by nondepolarising muscle relaxants.

Uingereza - Kiingereza - MHRA (Medicines & Healthcare Products Regulatory Agency)

advanz pharma - glycopyrronium bromide - solution for injection - 200microgram/1ml

Uingereza - Kiingereza - MHRA (Medicines & Healthcare Products Regulatory Agency)

advanz pharma - glycopyrronium bromide - solution for injection - 200microgram/1ml

Uingereza - Kiingereza - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord-uk ltd - glycopyrronium bromide - solution for injection - 200microgram/1ml

Uingereza - Kiingereza - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord-uk ltd - glycopyrronium bromide - solution for injection - 200microgram/1ml

Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - glycopyrronium bromide 0.063mg equivalent to glycopyrronium 0.05 mg;   - powder filled inhalation capsule - 50 mcg - active: glycopyrronium bromide 0.063mg equivalent to glycopyrronium 0.05 mg   excipient: lactose monohydrate magnesium stearate orange capsule (novartis) - once-daily maintenance bronchodilator treatment to relieve symptoms of patients with chronic obstructive pulmonary disease (copd).

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - indacaterol acetate, quantity: 173 microgram (equivalent: indacaterol, qty 150 microgram); mometasone furoate, quantity: 160 microgram; glycopyrronium bromide, quantity: 63 microgram (equivalent: glycopyrronium, qty 50 microgram) - capsule, hard - excipient ingredients: lactose monohydrate; magnesium stearate - enerzair breezhaler is indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long-acting beta2-agonist and an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

mercurypharm ltd - glycopyrronium bromide; neostigmine metilsulfate - solution for injection - 0.5mg /2.5 milligram(s)/millilitre - anticholinesterases; neostigmine, combinations

Uingereza - Kiingereza - myHealthbox

dawa limited - glycopyrronium bromide - tablets - 1mg - anticholinergic - for use in adults as add-on therapy in the treatment of peptic ulcer